"research and development expenses decreased by 8.5% to A$12.65 million"
Yet general expenses (wages, photocopier haha) huge increase
I would have thought R&D (bread and butter and core function of a clinical stage bio) would have increased with the five IP products, four of them at clinical trials ??
Analysts Reports (Imugene), page-302
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
0.004(8.16%) |
Mkt cap ! $394.1M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.5¢ | 4.8¢ | $1.798M | 35.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 2193808 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 605064 | 3 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |